Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer

Abstract Androgen receptor (AR) inhibition is standard of care for advanced prostate cancer (PC). However, efficacy is limited by progression to castration-resistant PC (CRPC), usually due to AR re-activation via mechanisms that include AR amplification and structural rearrangement. These two classes of AR alterations often co-occur in CRPC tumors, but it is unclear whether this reflects intercellular or intracellular heterogeneity of AR. Resolving this is important for developing new therapies and predictive biomarkers. Here, we analyzed 41 CRPC tumors and 6 patient-derived xenografts (PDXs) using linked-read DNA-sequencing, and identified 7 tumors that developed complex, multiply-rearranged AR gene structures in conjunction with very high AR copy number. Analysis of PDX models by optical genome mapping and fluorescence in situ hybridization showed that AR residing on extrachromosomal DNA (ecDNA) was an underlying mechanism, and was associated with elevated levels and diversity of AR expression. This study identifies co-evolution of AR gene copy number and structural complexity via ecDNA as a mechanism associated with endocrine therapy resistance.

[1]  B. Regenberg,et al.  Extrachromosomal circular DNA in cancer: history, current knowledge, and methods. , 2022, Trends in genetics : TIG.

[2]  M. Meyerson,et al.  Patterns of structural variation define prostate cancer across disease states , 2022, bioRxiv.

[3]  J. Welti,et al.  A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. , 2021, Annual review of pharmacology and toxicology.

[4]  J. Lang,et al.  AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer. , 2021, Endocrine-Related Cancer.

[5]  M. Nykter,et al.  Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition , 2021, Clinical Cancer Research.

[6]  Henry W. Long,et al.  MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets , 2021, Nature Communications.

[7]  L. Dennis,et al.  Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms , 2021, Clinical Cancer Research.

[8]  Jeffrey M. McManus,et al.  Hormonal Therapy for Prostate Cancer. , 2021, Endocrine reviews.

[9]  D. Torrents,et al.  Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma , 2020, Nature Communications.

[10]  Howard Y. Chang,et al.  Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers , 2020, Nature Genetics.

[11]  Yong Wang,et al.  Ultralow-input single-tube linked-read library method enables short-read second-generation sequencing systems to routinely generate highly accurate and economical long-range sequencing information , 2020, Genome research.

[12]  C. Maher,et al.  Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer , 2020, Clinical Cancer Research.

[13]  D. Torrents,et al.  Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma , 2019, Nature Genetics.

[14]  Richard C. Sallari,et al.  Functional Enhancers Shape Extrachromosomal Oncogene Amplifications , 2019, Cell.

[15]  J. Gregg,et al.  Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors , 2019, JCO precision oncology.

[16]  Yi Mi Wu,et al.  Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.

[17]  Hanlee P. Ji,et al.  Structural variant analysis for linked-read sequencing data with gemtools , 2019, Bioinform..

[18]  S. Gregory,et al.  Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Tammela,et al.  Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer , 2019, The New England journal of medicine.

[20]  Shivakumar Keerthikumar,et al.  Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. , 2018, European urology.

[21]  P. Nelson,et al.  Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer , 2018, The Journal of clinical investigation.

[22]  S. Sleijfer,et al.  TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer , 2018, Clinical Cancer Research.

[23]  William Stafford Noble,et al.  Integrative detection and analysis of structural variation in cancer genomes , 2018, Nature Genetics.

[24]  Christopher W. Whelan,et al.  Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing , 2018, Cell.

[25]  Joshua M. Stuart,et al.  Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer , 2018, Cell.

[26]  Henry W. Long,et al.  A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer , 2018, Cell.

[27]  F. Saad,et al.  Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.

[28]  Michael D. Nyquist,et al.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.

[29]  Benjamin J. Raphael,et al.  Identifying structural variants using linked-read sequencing data , 2017, bioRxiv.

[30]  J. Lindberg,et al.  Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns. , 2017, European urology.

[31]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[32]  Tyson A. Clark,et al.  Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance , 2017, Clinical Cancer Research.

[33]  P. Nelson,et al.  LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics , 2017, The Prostate.

[34]  Jessica M. Rusert,et al.  Extrachromosomal oncogene amplification drives tumor evolution and genetic heterogeneity , 2017, Nature.

[35]  Sean R. Landman,et al.  Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer , 2016, Nature Communications.

[36]  J. Luo,et al.  Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting , 2016, Prostate Cancer and Prostatic Disease.

[37]  J. Shendure,et al.  Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer , 2016, Nature Medicine.

[38]  Hanlee P. Ji,et al.  Haplotyping germline and cancer genomes using high-throughput linked-read sequencing , 2015, Nature Biotechnology.

[39]  Serafim Batzoglou,et al.  Read clouds uncover variation in complex regions of the human genome , 2015, RECOMB.

[40]  M. Nykter,et al.  The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.

[41]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[42]  Michael D. Nyquist,et al.  TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer , 2013, Proceedings of the National Academy of Sciences.

[43]  R. Vessella,et al.  Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration‐resistant prostate cancer: Results from the University of Washington Rapid Autopsy Series , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[45]  Gabor T. Marth,et al.  Haplotype-based variant detection from short-read sequencing , 2012, 1207.3907.

[46]  R. Vessella,et al.  AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression , 2011, Oncogene.

[47]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[48]  Oscar Lin,et al.  Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer , 2009, Clinical Cancer Research.

[49]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[50]  H. Scher,et al.  Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.

[51]  F. Apiou,et al.  Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Hamid Bolouri,et al.  Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer , 2016 .

[53]  F. Saad,et al.  Enzalutamide in Metastatic Prostate Cancer before Chemotherapy , 2014 .

[54]  K. Silverstein,et al.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. , 2013, Cancer research.

[55]  Majid I. Alsagabi,et al.  Molecular and Cellular Pathobiology Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression , 2011 .